New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation

Transcription

1 New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation Dr. Klaus Suwelack Johnson & Johnson Innovation, Janssen-Cilag Germany, Neuss May 11 th,

2 Johnson & Johnson: A leading global health care company. Revenue 2013: 71,3 bn $ U.S. One of the LEADING health care companies Eighth largest pharmaceutical company Sixth largest Biotech company More than 250 operating companies in 60 countries Products are offered in 175 countries More than employees MEDICAL DEVICES & DIAGNOSTICS CONSUMER PHARMACEUTICALS 2

3 Janssen Company Profile Who We Are One of the LEADING PHARMACEUTICAL RESEARCH COMPANIES 2014 sales: Approx. EUR 26.6 BIL. EUR1.04 BIL. in GERMANY 62 years 4 Founded in 1953 in GERMANY since 1959 PART OF JOHNSON & JOHNSON since 1961 Key therapeutic areas: INFECTIOUS DISEASES IMMUNOLOGY ONCOLOGY NEUROLOGY/PSYCHIATRY Employees around the world: Approx. 40,000 Approx. 800 in Germany 6 ACTIVE COMPOUNDS on the WHO LIST OF ESSENTIAL MEDICINES Active on 5 continents 8 10 research and development centers, Production sites IN EUROPE Last updated: March

4 Janssen Company Profile Our Key Therapeutic Areas Neurology Psychiatry Infectious Diseases Immunology Oncology ADHD Dementia Hepatitis C HIV/AIDS Asthma Psoriasis Anemia in cancer patients Multiple myeloma Epilepsy Schizophrenia Tuberculosis Psoriatic arthritis Prostate cancer Breast cancer Ovarian cancer Pain Acute myeloid leukemia Castleman disease Chronic lymphoid leukemia Mantle cell lymphoma 4

5 Our Identity In the Tradition of Our Founder Time is precious, we are running out of it, and the patients are waiting. Dr. Paul Janssen ( ) 5

6 External Innovation Percentage of drugs under development that were initially developed at another company 50% 33% 16% 20% Source: Medtrack; Johnson & Johnson The Wall Street Journal Top 10 Pharmaceutical companies

7 Our R&D Strategy: Focus on Transformational Innovation that Solves Unmet Medical Need Medical need and differentiation Deep scientific and medical expertise Select the best science internal and external Excellence in global execution Speed to market

8 Our Approach to Sourcing Innovation Internal Discovery & Early Research Biomarkers, Research Capabilities Global Development Early Exploration Discovery Concept Early Development Late Development Regulatory Approval Post Launch Innovation Centres Business Development Johnson & Johnson Development Corporation 8

9 We Find the Best Science "The world is our lab" Licensing & Acquisitions Internal Research External Collaborations Academia Biotech Pharma Consortia 9

10 Innovation is everywhere, but mostly outside of our own organization California London Boston Russia Shanghai San Diego Israel Japan Singapore Innovation Center Satellite Australia

11 Extending Network through Local Scouts Innovation Centers: Local Scouts reach out to extend coverage in several European countries Scanning for opportunities and liaising with biotech & academia and maintaining interactions with partner organizations (Moscow) (Israel) 11

12 Pharmaceuticals Our Janssen Pharmaceutical business is one of the most productive and innovative in the world. In the past 10 years, we have brought more differentiated pharmaceutical products to patients than any other company. The teams at the Johnson & Johnson Innovation Centers are interested in exploring early stage therapeutic and vaccine technologies up to clinical proof of concept in the following areas: Cardiovascular and Metabolism Type 2 Diabetes Heart Failure Immunology Rheumatoid Arthritis Inflammatory Bowel Disease Psoriasis Pulmonary Infectious Diseases and Vaccines Hepatitis Respiratory Infections Neuroscience Mood Disorders Alzheimer s Disease Pain Oncology Prostate Cancer Lung Cancer Hematologic Malignancies Colorectal Cancer 12

13 What We Consider & How We Prioritize Conviction level of experts in science & target Ability to establish pre-clinical and clinical POC Time and cost to preclinical and clinical POC Leadership potential (competitive landscape) Strategic fit for J&J IP strength Collaboration capability of partner Patient impact (medical need) Societal impact (e.g. patient years) Transformative potential at time of launch Cost of access (deal terms) Delivering Clinical POC products POC Proof of Concept 13

14 Co-creation Model Facilities (Labs, offices) R&D capabilities Investment J&J Innovation Centers providing access to.. Expertise Innovator Product Idea Products for Patients Advancing innovative products by enabling access to a full range of incubation ingredients supplied by network of strategic partners 14

15 Partnership Model: Flexible and Custom Right Opportunity Right Solution From transformational ideas through clinical proof of concept Ideas / Concepts Scientific Methods Technologies + Tools Diagnostics Pharmaceuticals Consumer Products Medical Devices Strategically aligned J&J Innovation areas of focus Janssen Labs or Janssen Labs@ Advice + Mentorship Partnering Offices: J&J Innovation@ J&J Innovator & EIR Program Incubation & Seed Financing Venture Financing Investment Partners Strategic LP Relationships R&D Collaborations Soft and Call Options Licensing Acquisition

16 Catalyzing innovation at Johnson & Johnson is about creating strong networks of people who can combine resources, ideas and technologies in a new way. Paul Stoffels, MD Chief Scientific Officer

17 Thank you Questions? Dr. Klaus Suwelack ksuwelac@its.jnj.com 17